Posted by Michael Wonder on 29 Jun 2021
MediWound receives complete response letter from US FDA for NexoBrid biologics license application
29 June 2021 - Company remains committed to working with FDA toward a potential approval for this important therapy.
MediWound today announced it received a complete response letter from the US FDA regarding the biologics license application seeking approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
